Skip to main content

KORSUVA (Vifor Pharma Pty Ltd)

Product name
KORSUVA
Date registered
Evaluation commenced
Decision date
Approval time
211 (255 working days)
Active ingredients
difelikefalin acetate
Registration type
NCE/NBE
Indication

KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

Help us improve the Therapeutic Goods Administration site